Development of therapeutic antibodies for the treatment of diseases
Abstract It has been more than three decades since the first monoclonal antibody was approved by the United States Food and Drug Administration (US FDA) in 1986, and during this time, antibody engineering has dramatically evolved. Current antibody drugs have increasingly fewer adverse effects due to...
Main Authors: | Ruei-Min Lu, Yu-Chyi Hwang, I-Ju Liu, Chi-Chiu Lee, Han-Zen Tsai, Hsin-Jung Li, Han-Chung Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-01-01
|
Series: | Journal of Biomedical Science |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12929-019-0592-z |
Similar Items
-
Animal- versus in vitro-derived antibodies: avoiding the extremes
by: Andrew R.M. Bradbury, et al.
Published: (2021-01-01) -
Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries
by: Andre Azevedo Reis Teixeira, et al.
Published: (2021-01-01) -
Evolution of phage display libraries for therapeutic antibody discovery
by: Yang Zhang
Published: (2023-12-01) -
In vivo Phage Display: A promising selection strategy for the improvement of antibody targeting and drug delivery properties
by: Ana S. André, et al.
Published: (2022-09-01) -
Generation of hapten-specific recombinant antibodies: antibody phage display technology: a review
by: J. Brichta, et al.
Published: (2005-06-01)